HRP20151437T1 - Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline - Google Patents
Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline Download PDFInfo
- Publication number
- HRP20151437T1 HRP20151437T1 HRP20151437TT HRP20151437T HRP20151437T1 HR P20151437 T1 HRP20151437 T1 HR P20151437T1 HR P20151437T T HRP20151437T T HR P20151437TT HR P20151437 T HRP20151437 T HR P20151437T HR P20151437 T1 HRP20151437 T1 HR P20151437T1
- Authority
- HR
- Croatia
- Prior art keywords
- zinc
- use according
- preparation
- composition
- amino acid
- Prior art date
Links
- 230000027119 gastric acid secretion Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003751 zinc Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 8
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims 6
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims 4
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims 4
- 239000000612 proton pump inhibitor Substances 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 4
- 239000004246 zinc acetate Substances 0.000 claims 4
- 229940056904 zinc ascorbate Drugs 0.000 claims 4
- 239000011592 zinc chloride Substances 0.000 claims 4
- 235000005074 zinc chloride Nutrition 0.000 claims 4
- 239000011746 zinc citrate Substances 0.000 claims 4
- 235000006076 zinc citrate Nutrition 0.000 claims 4
- 229940068475 zinc citrate Drugs 0.000 claims 4
- 239000011670 zinc gluconate Substances 0.000 claims 4
- 235000011478 zinc gluconate Nutrition 0.000 claims 4
- 229960000306 zinc gluconate Drugs 0.000 claims 4
- 229940032991 zinc picolinate Drugs 0.000 claims 4
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 claims 4
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 claims 4
- 210000004051 gastric juice Anatomy 0.000 claims 3
- 229960000314 zinc acetate Drugs 0.000 claims 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 3
- 229960001763 zinc sulfate Drugs 0.000 claims 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000013522 chelant Substances 0.000 claims 2
- 229960004770 esomeprazole Drugs 0.000 claims 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical group C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 2
- 229960003174 lansoprazole Drugs 0.000 claims 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 2
- 229960000381 omeprazole Drugs 0.000 claims 2
- 229960005019 pantoprazole Drugs 0.000 claims 2
- 229960004157 rabeprazole Drugs 0.000 claims 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 2
- 229960001939 zinc chloride Drugs 0.000 claims 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- -1 L- glycinate Chemical compound 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011667 zinc carbonate Substances 0.000 claims 1
- 235000004416 zinc carbonate Nutrition 0.000 claims 1
- 229910000010 zinc carbonate Inorganic materials 0.000 claims 1
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 claims 1
- 239000011576 zinc lactate Substances 0.000 claims 1
- 235000000193 zinc lactate Nutrition 0.000 claims 1
- 229940050168 zinc lactate Drugs 0.000 claims 1
- 229940118257 zinc undecylenate Drugs 0.000 claims 1
- VRGNUPCISFMPEM-ZVGUSBNCSA-L zinc;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VRGNUPCISFMPEM-ZVGUSBNCSA-L 0.000 claims 1
- JNPQFTCBVDSMDO-UHFFFAOYSA-L zinc;2,3-dihydroxypropanoate Chemical compound [Zn+2].OCC(O)C([O-])=O.OCC(O)C([O-])=O JNPQFTCBVDSMDO-UHFFFAOYSA-L 0.000 claims 1
- MCOGTQGPHPAUJN-UHFFFAOYSA-L zinc;2-hydroxyacetate Chemical compound [Zn+2].OCC([O-])=O.OCC([O-])=O MCOGTQGPHPAUJN-UHFFFAOYSA-L 0.000 claims 1
- WDHVIZKSFZNHJB-UHFFFAOYSA-L zinc;butanoate Chemical compound [Zn+2].CCCC([O-])=O.CCCC([O-])=O WDHVIZKSFZNHJB-UHFFFAOYSA-L 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (16)
1. Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
2. Pripravak za uporabu prema zahtjevu 1 gdje je ta količina cinkove soli u tom pripravku učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 3.5 u vremenu ne većem od 30 minuta nakon primjene.
3. Pripravak za uporabu prema zahtjevu 1 ili 2 gdje je ta količina cinkove soli učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 4.0.
4. Pripravak za uporabu prema bilo kojem od zahtjeva 1-3 gdje se ta cinkova sol izabire iz grupe koju čine cinkov acetat, cinkov askorbat, cinkov butirat, cinkov karbonat, cinkov citrat, cinkov klorid, cinkov jodid, cinkov sulfat, cinkov glukonat, cinkov glicerat, cinkov glikolat, cinkov format, cinkov laktat, cinkov pikolinat, cinkov salicilat, cinkov tartarat, cinkov undecilenat, cinkov aminokiselinski kelat i njihove mješavine.
5. Pripravak za uporabu prema zahtjevu 4 gdje se ta cinkova sol izabire iz grupe koju čine cinkov acetat, cinkov askorbat, cinkov citrat, cinkov klorid, cinkov sulfat, cinkov glukonat, cinkov pikolinat, cinkov aminokiselinski kelat ili njihove mješavine.
6. Pripravak za uporabu prema bilo kojem od zahtjeva 3 gdje se ta cinkova sol izabire između barem dvije cinkove soli iz grupe koju čine cinkov acetat, cinkov askorbat, cinkov citrat, cinkov klorid, cinkov glukonat, cinkov pikolinat i cinkov aminokiselinski kelat.
7. Pripravak za uporabu prema zahtjevu 1-6 gdje je ta cinkova sol ili barem jedna od cinkovih soli cinkov aminokiselinski kelat.
8. Pripravak za uporabu prema zahtjevu 7 gdje se taj cinkov aminokiselinski kelat izabire iz grupe koju čine mono- i bis-kelati L- ili D- aminokiselina.
9. Pripravak za uporabu prema zahtjevu 7 ili 8 gdje taj aminokiselinski kelat jest cinkov kelat s aminokiselinom izabranom iz grupe koju čine L-cistein, L-cistin, L-N-acetilcistein, L-histidin, D-histidin, L-taurin, L-glicinat, L-aspartat i L-metionin.
10. Pripravak za uporabu prema bilo kojem od zahtjeva 1-3 gdje ta cinkova sol jest cinkov klorid i po izboru, barem jedna dodatna cinkova sol izabrana iz grupe koju čine cinkov acetat, cinkov askorbat, cinkov citrat, cinkov glukonat, cinkov pikolinat, cinkov sulfat i cinkov aminokiselinski kelat.
11. Pripravak za uporabu prema bilo kojem od zahtjeva 1-10 gdje je inhibitor protonske pumpe esomeprazol, lanzoprazol, omeprazol, pantoprazol, rabeprazol ili njihove mješavine.
12. Pripravak za uporabu prema bilo kojem od zahtjeva 1-11 gdje je taj inhibitor protonske pumpe mješavina esomeprazola, lanzoprazola, omeprazola, pantoprazola ili rabeprazola.
13. Pripravak za uporabu prema bilo kojem od zahtjeva 1-11 gdje je taj inhibitor protonske pumpe formuliran u obliku prilagođenog oslobađanja.
14. Pripravak za uporabu prema bilo kojem od zahtjeva 1-13 koji sadrži najmanje dvije cinkove soli, barem jedna od tih cinkovih soli je formulirana u obliku koji se odmah oslobađa i barem jedna cinkova sol je formulirana u obliku prilagođenog oslobađanja.
15. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je pripravak tekući pripravak.
16. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je pripravak prikladan za oralnu primjenu.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76259506P | 2006-01-27 | 2006-01-27 | |
| US76483406P | 2006-02-03 | 2006-02-03 | |
| US85089106P | 2006-10-11 | 2006-10-11 | |
| EP07716990.2A EP1976532B1 (en) | 2006-01-27 | 2007-01-25 | Fast acting inhibitor of gastric acid secretion |
| PCT/US2007/001950 WO2007089511A2 (en) | 2006-01-27 | 2007-01-25 | Fast acting inhibitor of gastric acid secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151437T1 true HRP20151437T1 (hr) | 2016-02-12 |
Family
ID=38327882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151437TT HRP20151437T1 (hr) | 2006-01-27 | 2015-12-30 | Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11510894B2 (hr) |
| EP (2) | EP1976532B1 (hr) |
| JP (3) | JP5469865B2 (hr) |
| CN (2) | CN103463096B (hr) |
| CA (1) | CA2635272C (hr) |
| DK (1) | DK1976532T3 (hr) |
| ES (2) | ES2609976T3 (hr) |
| HK (1) | HK1191861A1 (hr) |
| HR (1) | HRP20151437T1 (hr) |
| HU (1) | HUE029222T2 (hr) |
| PL (1) | PL1976532T3 (hr) |
| PT (1) | PT1976532E (hr) |
| RS (1) | RS54543B1 (hr) |
| SI (1) | SI1976532T1 (hr) |
| WO (1) | WO2007089511A2 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609976T3 (es) | 2006-01-27 | 2017-04-25 | Yale University | Combinación de sal de cinc y agente anti-H. pylori como inhibidor de acción rápida de la secreción de ácido gástrico |
| US8512761B2 (en) | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| US20120232158A1 (en) * | 2008-03-03 | 2012-09-13 | Yale Univeristy | Methods of treating hyperacidic disorders |
| JP2010184914A (ja) * | 2009-02-13 | 2010-08-26 | Bizen Chemical Co Ltd | プロトンポンプ阻害活性を有する組成物 |
| US20110038852A1 (en) * | 2009-06-10 | 2011-02-17 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
| CA2779518A1 (en) * | 2009-11-01 | 2011-05-05 | Synthetic Biologics, Inc. | Gastroretentive oral high dose zinc preparations |
| DK2568987T3 (en) | 2010-05-12 | 2017-02-20 | Rempex Pharmaceuticals Inc | Tetracycline COMPOSITIONS |
| US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| WO2015153552A1 (en) * | 2014-03-31 | 2015-10-08 | Yale University | Fast acting inhibitor of gastric acid secretion with enhanced activity |
| CN105232506A (zh) * | 2015-11-04 | 2016-01-13 | 温州医科大学 | 丁酸及其盐在制备治疗或预防胃溃疡药物中的应用 |
| CN105769840B (zh) * | 2016-04-01 | 2018-06-29 | 温州医科大学 | 乙酸及其盐的应用 |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
| MX2021007095A (es) * | 2018-12-20 | 2021-08-11 | Colgate Palmolive Co | Composicion de cuidado bucal que comprende zinc y un aminoacido para tratar los sintomas de un trastorno gastrico en la cavidad bucal. |
| CN111388436A (zh) * | 2020-04-20 | 2020-07-10 | 北京健讯医药科技有限公司 | 一种海藻酸钠咀嚼片及其制备方法 |
| CN114908314B (zh) * | 2022-05-16 | 2023-11-28 | 浙江飞剑工贸有限公司 | 一种能持久微量释放金属离子的抗菌涂层及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE393532B (sv) * | 1974-05-02 | 1977-05-16 | Draco Ab | Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex |
| US4863741A (en) | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| GB2196252B (en) | 1986-09-18 | 1990-10-17 | London Pharmacy Innovation | Gastric controlled-release dosage forms |
| JPH07116160B2 (ja) | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性ｌ−カルノシン亜鉛錯体およびその製造法 |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| AUPM456894A0 (en) * | 1994-03-18 | 1994-04-14 | Glyzinc Pharmaceuticals Limited | Treatment for gastric disorders |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| HU225329B1 (en) * | 1996-09-12 | 2006-09-28 | Richter Gedeon Vegyeszet | Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity |
| GB9621273D0 (en) | 1996-10-11 | 1996-11-27 | Cortecs Ltd | Therapeutic method |
| US20030068326A1 (en) * | 1998-05-15 | 2003-04-10 | Aphton Corporation | Method for the treatment of gastroesophageal reflux disease |
| US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
| US6166071A (en) * | 2000-03-13 | 2000-12-26 | Albion International, Inc. | Zinc amino acid chelates having ligands comprised of glycine and a sulfur-containing amino acids |
| US6576634B1 (en) * | 2000-07-07 | 2003-06-10 | N.V. Nutricia | Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality |
| JP2004505046A (ja) * | 2000-07-28 | 2004-02-19 | イムファルム・アンパルトセルスカブ | 感冒、アレルギー性鼻炎および気道に関連した感染症の症状の処置方法 |
| US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
| US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
| EP1262172A1 (en) * | 2001-05-25 | 2002-12-04 | Italmed S.N.C. Di Galli G. & Pacini G. | Liquid polymer composition for prevention and treatment of the oral cavity diseases |
| US7026298B2 (en) * | 2001-06-04 | 2006-04-11 | Abbott Laboratories | Oral rehydration compositions |
| FI20011403A (fi) * | 2001-06-29 | 2002-12-30 | Carbion Oy | Menetelmä ja koostumukset vatsan sairauksien hoitoon |
| US6596708B1 (en) * | 2001-09-07 | 2003-07-22 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
| US6930099B2 (en) * | 2001-09-07 | 2005-08-16 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
| US6632449B2 (en) * | 2001-11-20 | 2003-10-14 | The Procter & Gamble Co. | Compositions and kits comprising a defined boron compound and methods of their preparation |
| EP1480517A4 (en) | 2002-02-07 | 2007-08-22 | Univ Columbia | ZINC SALT COMPOSITIONS FOR PREVENTING MOLECULAR BREAST EXTRACTION THROUGH SPERMICIDES AND MICROBICIDES |
| JP2006518751A (ja) * | 2003-02-20 | 2006-08-17 | サンタラス インコーポレイティッド | 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物 |
| WO2004099182A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Zinc salt of (s)-omeprazole |
| MXPA05011699A (es) | 2003-05-06 | 2006-01-23 | Altana Pharma Ag | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. |
| US7871649B2 (en) * | 2003-07-17 | 2011-01-18 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| MXPA06000652A (es) | 2003-07-23 | 2006-03-30 | Altana Pharma Ag | Sales alcalinas de inhibidores de bomba de protones. |
| AU2004287485A1 (en) * | 2003-11-05 | 2005-05-19 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
| US20050238731A1 (en) * | 2003-12-29 | 2005-10-27 | Stephen Holt | Composition and method for treating the effects of diseases and maladies of the upper digestive tract |
| JP2007522217A (ja) | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
| US20060160783A1 (en) | 2004-12-30 | 2006-07-20 | Transform Pharmaceuticals, Inc. | Novel omeprazole forms and related methods |
| EP1830832A1 (en) | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
| CN100515491C (zh) * | 2005-01-04 | 2009-07-22 | 健能隆医药技术（上海）有限公司 | 白介素-22的医药用途 |
| US20060230553A1 (en) * | 2005-04-14 | 2006-10-19 | Helmut Thullen | Process for tinting, dyeing or doping of moulded components made of transparent (co)polyamides in aqueous dye bath |
| US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
| US8512761B2 (en) | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| ES2609976T3 (es) | 2006-01-27 | 2017-04-25 | Yale University | Combinación de sal de cinc y agente anti-H. pylori como inhibidor de acción rápida de la secreción de ácido gástrico |
-
2007
- 2007-01-25 ES ES13193624.7T patent/ES2609976T3/es active Active
- 2007-01-25 WO PCT/US2007/001950 patent/WO2007089511A2/en active Application Filing
- 2007-01-25 US US12/086,379 patent/US11510894B2/en active Active
- 2007-01-25 DK DK07716990.2T patent/DK1976532T3/en active
- 2007-01-25 RS RS20160022A patent/RS54543B1/en unknown
- 2007-01-25 CA CA2635272A patent/CA2635272C/en active Active
- 2007-01-25 CN CN201310174056.4A patent/CN103463096B/zh not_active Expired - Fee Related
- 2007-01-25 CN CN2007800036618A patent/CN101374526B/zh not_active Expired - Fee Related
- 2007-01-25 EP EP07716990.2A patent/EP1976532B1/en active Active
- 2007-01-25 EP EP13193624.7A patent/EP2705845B1/en active Active
- 2007-01-25 JP JP2008552394A patent/JP5469865B2/ja not_active Expired - Fee Related
- 2007-01-25 ES ES07716990.2T patent/ES2562059T3/es active Active
- 2007-01-25 HU HUE07716990A patent/HUE029222T2/en unknown
- 2007-01-25 SI SI200731736T patent/SI1976532T1/sl unknown
- 2007-01-25 PT PT77169902T patent/PT1976532E/pt unknown
- 2007-01-25 PL PL07716990T patent/PL1976532T3/pl unknown
-
2013
- 2013-08-12 JP JP2013167225A patent/JP2013241457A/ja active Pending
-
2014
- 2014-05-30 HK HK14105100.0A patent/HK1191861A1/zh not_active IP Right Cessation
-
2015
- 2015-08-06 JP JP2015155729A patent/JP6366548B2/ja not_active Expired - Fee Related
- 2015-12-30 HR HRP20151437TT patent/HRP20151437T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013241457A (ja) | 2013-12-05 |
| CN103463096A (zh) | 2013-12-25 |
| JP6366548B2 (ja) | 2018-08-01 |
| CN101374526A (zh) | 2009-02-25 |
| EP1976532A4 (en) | 2010-12-15 |
| EP2705845A1 (en) | 2014-03-12 |
| DK1976532T3 (en) | 2016-02-01 |
| WO2007089511A3 (en) | 2008-04-10 |
| CN101374526B (zh) | 2013-08-07 |
| JP2009524669A (ja) | 2009-07-02 |
| CN103463096B (zh) | 2016-03-16 |
| ES2562059T3 (es) | 2016-03-02 |
| WO2007089511A2 (en) | 2007-08-09 |
| PT1976532E (pt) | 2016-02-11 |
| JP5469865B2 (ja) | 2014-04-16 |
| EP2705845B1 (en) | 2016-10-05 |
| EP1976532B1 (en) | 2015-11-11 |
| PL1976532T3 (pl) | 2016-05-31 |
| SI1976532T1 (sl) | 2016-04-29 |
| US20090035393A1 (en) | 2009-02-05 |
| HK1191861A1 (zh) | 2014-08-08 |
| JP2015232016A (ja) | 2015-12-24 |
| HUE029222T2 (en) | 2017-02-28 |
| CA2635272A1 (en) | 2007-08-09 |
| RS54543B1 (en) | 2016-06-30 |
| ES2609976T3 (es) | 2017-04-25 |
| EP1976532A2 (en) | 2008-10-08 |
| US11510894B2 (en) | 2022-11-29 |
| CA2635272C (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151437T1 (hr) | Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline | |
| WO2010062688A3 (en) | Dosage form for insertion into the mouth | |
| JP2010529018A5 (ja) | 医薬組成物、および医薬錠剤 | |
| AR070357A1 (es) | Producto para cuidado oral y metodos de uso y manufactura del mismo | |
| NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
| IL199234A (en) | A crystalline form of intrinsic elaprazole, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat infections of the digestive system @ | |
| JP2011502997A5 (hr) | ||
| JP2006518751A5 (hr) | ||
| MY145696A (en) | 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-menthyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament | |
| SMP200700047B (it) | Forme di dosaggio di risedronato | |
| MX2008011823A (es) | Forma de dosificacion solida que contiene un agente activo de sabor encubierto. | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| NZ607189A (en) | Materials and methods for improving gastrointestinal function | |
| JP2008526880A5 (hr) | ||
| WO1994002140A1 (en) | Pharmaceutical composition containing antiulcer agent | |
| JP2010539144A5 (hr) | ||
| RU2013117758A (ru) | Способы и композиции для лечения расстройств пищевода | |
| EA200702102A1 (ru) | Пластинки, содержащие стероидные гормоны | |
| PL363007A1 (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
| WO2006100595A3 (en) | Chewing gum compositions of varenicline | |
| CN101229162A (zh) | 含有右旋雷贝拉唑及其盐的冻干粉针制剂及其制备工艺 | |
| WO1994016688A1 (en) | Nutritive composition | |
| WO2005097083A3 (en) | Transdermal administration of proton pump inhibitors | |
| CN106620673A (zh) | 一种治疗小儿口腔溃疡的水凝胶及其制备方法 |